A randomized, double-blind, placebo-controlled, multicenter study to examine the effect of betahistine [OBE 101; OBEcure] on body weight gain due to olanzapine [Zyprexa; Eli Lilly] treatment
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Betahistine (Primary)
- Indications Weight gain
- Focus Therapeutic Use
- Sponsors OBEcure
- 30 Nov 2008 Status changed from recruiting to discontinued, based on information from ClinicalTrials.gov. This trial was terminated as interim results did not indicate a significant benefit (of the study drug) in terms of the primary endpoint.
- 23 Feb 2007 New trial record.